

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

March 7, 2023

Oncolys BioPharma Inc.

**Announcement of Completion of Enrollment
in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101)
in Patients with Amyotrophic Lateral Sclerosis (ALS)
and/or Frontotemporal Degeneration (FTD)**

Oncolys BioPharma Inc. (hereafter “Oncolys”) today announced that it has received a notice from Transposon Therapeutics, Inc. (“Transposon”), licensee of OBP-601 (censavudine, TPN-101), that enrollment has been completed in the Phase IIa, double-blind, placebo-controlled study of OBP-601 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Degeneration (FTD) who have the C9ORF72 repeat expansion mutation.

In addition, Transposon has completed enrollment in a Phase IIa, double-blind, placebo-controlled study of TPN-101 in patients with Progressive Supranuclear Palsy (PSP) as well as opened enrollment in a Phase IIa, Open Label study of TPN-101 in patients with Aicardi-Goutières Syndrome (AGS). (<https://clinicaltrials.gov/ct2/show/NCT05613868>)

###

About Oncolys BioPharma Inc.

Oncolys BioPharma Inc. (JPX:4588) develops novel cancer therapeutics and diagnostic products using gene modified viral technologies and aims to contribute to fulfill unmet medical needs for cancer and severe infectious diseases.

Especially in oncology area, we utilize technology platform for oncolytic virus and develop Telomelysin and its next-generations for cancer treatment and TelomeScan for early detection of cancer and recurrence monitoring after surgery. We have established broad range of product pipeline to cover early detection of cancer, early treatment of local cancer, post-operative examination, and treatment of metastatic cancer. For more information, please visit <http://www.oncolys.com/en/>

Contact:

Oncolys BioPharma Inc.

Email: oncolys_information@oncolys.com